Your browser doesn't support javascript.
loading
Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program.
Vacher, Laure; Thivat, Emilie; Poirier, Camille; Mouret-Reynier, Marie-Ange; Chollet, Philippe; Devaud, Hervé; Dubray-Longeras, Pascale; Kwiatkowski, Fabrice; Durando, Xavier; van Praagh-Doreau, Isabelle; Chevrier, Régine.
Afiliação
  • Vacher L; Oncology Department, Centre Jean Perrin, F-63011, Clermont-Ferrand, France. Laure.VACHER@clermont.unicancer.fr.
  • Thivat E; University Clermont 1, UFR Médecine, FR-63000, Clermont-Ferrand, France. Laure.VACHER@clermont.unicancer.fr.
  • Poirier C; Délégation Recherche Clinique & Innovation, Centre de Lutte contre le Cancer, 58 rue Montalembert, F-63000, Clermont-Ferrand, France.
  • Mouret-Reynier MA; Centre d'Investigation Clinique UMR 501, F-63001, Clermont-Ferrand, France.
  • Chollet P; Université Clermont Auvergne, Centre Jean Perrin, INSERM, UMR1240 Imagerie Moléculaire et Stratégies Théranostiques, FR-63000, Clermont-Ferrand, France.
  • Devaud H; Oncology Department, Centre Jean Perrin, F-63011, Clermont-Ferrand, France.
  • Dubray-Longeras P; Oncology Department, Centre Jean Perrin, F-63011, Clermont-Ferrand, France.
  • Kwiatkowski F; Université Clermont Auvergne, Centre Jean Perrin, INSERM, UMR1240 Imagerie Moléculaire et Stratégies Théranostiques, FR-63000, Clermont-Ferrand, France.
  • Durando X; Oncology Department, Centre Jean Perrin, F-63011, Clermont-Ferrand, France.
  • van Praagh-Doreau I; Délégation Recherche Clinique & Innovation, Centre de Lutte contre le Cancer, 58 rue Montalembert, F-63000, Clermont-Ferrand, France.
  • Chevrier R; Centre d'Investigation Clinique UMR 501, F-63001, Clermont-Ferrand, France.
Support Care Cancer ; 28(7): 3313-3322, 2020 Jul.
Article em En | MEDLINE | ID: mdl-31758323
PURPOSE: A patient non-adherence with oral anticancer agents is a well-recognized barrier to effective treatment. The aim of this prospective study was to evaluate the efficacy of a therapeutic education program among non-adherent patients treated with Capecitabine alone or associated with Lapatinib. METHODS: Sixty-five cancer patients were enrolled. Among them, 55 participated in the first observational phase of the study, measuring adherence using electronic MEMS pillboxes (medication event monitoring system). An adherence score was assessed in the form of a composite adherence score including intake dose and intake intervals. Ten non-adherent patients (adherence score < 80%) were included in the intervention phase of the study and were enrolled on a therapeutic education program. The efficacy of the program was evaluated on the basis of an improvement in adherence scores. We also studied factors influencing adherence. RESULTS: The average adherence score was 83.6 ± 15.7% in the overall population. Forty-one patients were adherent (adherence score > 80%) and 14 patients were non-adherent (adherence score < 80%). The therapeutic education program for non-adherent patients (n = 10) increased their adherence score by 17.8% and led 60% of these patients to become adherent. The number of toxicities during the first cycles was a predictive factor for non-adherence. CONCLUSION: This study showed an improvement in adherence to Capecitabine ± Lapatinib among non-adherent patients by way of a therapeutic education program.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Adesão à Medicação / Capecitabina / Lapatinib / Neoplasias Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Adesão à Medicação / Capecitabina / Lapatinib / Neoplasias Idioma: En Ano de publicação: 2020 Tipo de documento: Article